SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-15-177069
Filing Date
2015-05-07
Accepted
2015-05-07 16:04:52
Documents
8
Effectiveness Date
2015-05-07

Document Format Files

Seq Description Document Type Size
1 DEFA141 d904982ddefa14a.htm DEFA14A 31964
2 GRAPHIC g904982na_pg001a.jpg GRAPHIC 10192
3 GRAPHIC g904982na_pg001b.jpg GRAPHIC 1692
4 GRAPHIC g904982na_pg001c.jpg GRAPHIC 1407
5 GRAPHIC g904982na_pg001d.jpg GRAPHIC 9954
6 GRAPHIC g904982na_pg001e.jpg GRAPHIC 7659
7 GRAPHIC g904982na_pg001f.jpg GRAPHIC 9746
8 GRAPHIC g904982na_pg001g.jpg GRAPHIC 4688
  Complete submission text file 0001193125-15-177069.txt   96533
Mailing Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142 617-871-9911
Eleven Biotherapeutics, Inc. (Filer) CIK: 0001485003 (see all company filings)

IRS No.: 252025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36296 | Film No.: 15841690
SIC: 2834 Pharmaceutical Preparations